Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Research & Development (2022 - 2025)

Axsome Therapeutics' Research & Development history spans 4 years, with the latest figure at $48.8 million for Q4 2025.

  • For Q4 2025, Research & Development fell 11.3% year-over-year to $48.8 million; the TTM value through Dec 2025 reached $183.3 million, down 2.03%, while the annual FY2025 figure was $183.3 million, 2.03% down from the prior year.
  • Research & Development for Q4 2025 was $48.8 million at Axsome Therapeutics, up from $40.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $55.0 million in Q4 2024 and bottomed at $12.6 million in Q1 2022.
  • The 4-year median for Research & Development is $33.8 million (2023), against an average of $32.9 million.
  • The largest annual shift saw Research & Development surged 142.23% in 2024 before it dropped 11.51% in 2025.
  • A 4-year view of Research & Development shows it stood at $14.7 million in 2022, then soared by 109.65% to $30.8 million in 2023, then surged by 78.57% to $55.0 million in 2024, then fell by 11.3% to $48.8 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Research & Development are $48.8 million (Q4 2025), $40.2 million (Q3 2025), and $49.5 million (Q2 2025).